Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Marinomed Biotechnologie GMBH

This article was originally published in Start Up

Executive Summary

Marinomed Biotechnologie, which derives drugs from marine sources, is eyeing both the OTC and prescription markets. The Vienna-based start-up has already launched its first product: an OTC nasal spray formulation of a drug based on a polysaccharide extracted from seaweed. The company has in vitro and in vivo efficacy data for this compound against seasonal influenza, suggesting that it may also have potential for treating pandemic flu.

You may also be interested in...

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Start-Up Previews (06/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.

Start-Ups Set Sights on Flu

The swine flu/H1N1 pandemic presents a lucrative opportunity for drug developers and Big Pharmas won't be the only firms to capitalize on the sudden multibillion-dollar opportunity. There's evidence that the pandemic is driving investors to flu-focused biotechs as well. In this issue, we profile four emerging companies that hope to reap the rewards of what should continue to be a promising fund-raising environment for potentially novel flu therapies.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts